

IN THE CLAIMS

Please amend the claims as follows:

Claim 1 (Currently Amended): A composition comprising Use of a salt of L-ascorbic acid and with a pharmaceutically acceptable organic base to prepare a pharmaceutical composition, for ophthalmic topical use, capable of improving the level of L-ascorbic acid in a human eye.

Claim 2 (Currently Amended): The composition according to Claim 1, wherein Use according to Claim 1, characterized in that the said organic base is chosen selected from the group comprising consisting of tromethamine, N-methylglucosamine, lysine, arginine and ornithine.

Claim 3 (Currently Amended): The composition according to Claim 1, wherein Use according to Claim 1, characterized in that the said organic base is tromethamine or lysine.

Claim 4 (Currently Amended): The composition according to Claim 1, wherein Use according to any one of Claims 1 to 3, characterized in that the said composition is in the form of a cream or a sterile solution.

Claim 5 (Currently Amended): The composition according to Claim 1, wherein Use according to any one of Claims 1 to 4, characterized in that the said composition comprises contains from 0.1 to 20 mg/ml of the said salt of L-ascorbic acid with a the pharmaceutically acceptable organic base, and further comprises at least one pharmaceutically acceptable inert vehicle.

Claim 6 (Currently Amended): The composition according to Claim 5, wherein Use
~~according to Claim 5, characterized in that~~ the said composition ~~comprises~~ contains from 0.2
to 10 mg/ml of the said salt of L-ascorbic acid with a the pharmaceutically acceptable organic
base ~~and at least one pharmaceutically acceptable inert vehicle.~~

Claim 7 (Currently Amended): The composition according to Claim 5, wherein Use
~~according to Claim 5, characterized in that~~ the said composition ~~comprises~~ contains from 0.5
to 2 mg/ml of the said salt of L-ascorbic acid with a the pharmaceutically acceptable organic
base ~~and at least one pharmaceutically acceptable inert vehicle.~~

Claim 8 (Currently Amended): The composition according to Claim 1, wherein Use
~~according to any one of Claims 1 to 7, characterized in that~~ the said composition is in the
form of a sterile collyrium comprising a the salt of L-ascorbic acid with lysine or with
tromethamine.

Claim 9 (Currently Amended): The composition according to Claim 8, wherein Use
~~according to Claim 8, characterized in that~~ the said composition also further comprises an
anti-inflammatory drug.

Claim 10 (Currently Amended): The composition according to Claim 9, wherein Use
~~according to Claim 9, characterized in that~~ the said anti-inflammatory drug is dexamethasone.

Claim 11 (Currently Amended): A therapeutic ~~Therapeutic~~ method ~~for improving the~~
~~level of L-ascorbic acid in a human eye, the said method~~ comprising topically administering
~~the topical administration to the said eye of a composition, comprising an effective amount of~~

a salt of L-ascorbic acid with a pharmaceutically acceptable organic base, to an eye of a subject in need thereof.

Claim 12 (Currently Amended): The method Method according to Claim 11, wherein ~~in which~~ the said organic base is ~~chosen~~ selected from the group ~~comprising~~ consisting of tromethamine, N-methylglucosamine, lysine, arginine and ornithine.

Claim 13 (Currently Amended): The method Method according to Claim 11, wherein ~~in which~~ the said organic base is tromethamine or lysine.

Claim 14 (Currently Amended): The method Method according to ~~Claims 11 to 13~~ Claim 11, comprising the administration wherein the composition is administered 1 to 24 times a day in the form of a sterile pharmaceutical dosage ~~form comprising~~ containing from 0.1 to 20 mg/ml of the ~~said~~ salt.

Claim 15 (Currently Amended): The method Method according to ~~Claims 11 to 13~~ Claim 11, comprising the administration wherein the composition is administered 3 to 12 times a day in the form of a sterile pharmaceutical dosage ~~form comprising~~ containing from 0.1 to 20 mg/ml of the ~~said~~ salt.

Claim 16 (Currently Amended): The method Method according to ~~Claims 11 to 13~~ Claim 11, comprising the administration wherein the composition is administered 1 to 24 times a day in the form of a sterile pharmaceutical dosage ~~form comprising~~ containing from 0.2 to 10 mg/ml of the ~~said~~ salt.

Claim 17 (Currently Amended): ~~The method~~ Method according to ~~Claims 11 to 13~~
~~Claim 11, comprising the administration wherein the composition is administered~~ 3 to 12
times a day in the form of a sterile pharmaceutical dosage ~~form comprising~~ containing from
0.2 to 10 mg/ml of the ~~said~~ salt.

Claim 18 (Currently Amended): ~~The method~~ Method according to ~~Claims 11 to 13~~
~~Claim 11, comprising the administration wherein the composition is administered~~ 1 to 24
times a day in the form of a sterile pharmaceutical dosage ~~form comprising~~ containing from
0.5 to 2 mg/ml of the ~~said~~ salt.

Claim 19 (Currently Amended): ~~The method~~ Method according to ~~Claims 11 to 13~~
~~Claim 11, comprising the administration wherein the composition is administered~~ 3 to 12
times a day in the form of a sterile pharmaceutical dosage ~~form comprising~~ containing from
0.5 to 2 mg/ml of the ~~said~~ salt.

Claim 20 (Currently Amended): ~~The method~~ Method according to ~~Claims 11 to 19~~
~~Claim 11, also wherein the composition further comprises~~ comprising the ophthalmic topical
~~administration of an anti-inflammatory drug.~~

Claim 21 (Currently Amended): ~~The method~~ Method according to ~~Claims 11 to 20~~
~~Claim 20, also comprising the ophthalmic topical administration of~~ wherein the anti-
inflammatory drug is dexamethasone.